Salipro Biotech
Unlocking challenging drug targets for the development of next-generation therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Growth Equity VC | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 139 % | 157 % | (3 %) | 25 % | 107 % | (16 %) | 1 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (117 %) | (64 %) | (40 %) | (32 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (135 %) | (72 %) | (52 %) | (43 %) | (29 %) | (61 %) | (64 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Salipro Biotech specializes in stabilizing membrane proteins, which are crucial for drug discovery but inherently unstable and difficult to study. Using proprietary technology, Salipro Biotech reconstitutes these challenging targets while preserving their native structure and function in stable, lipid-containing nanoparticles. This allows for their use in various downstream applications, including antibody discovery and characterization. The company collaborates with top-tier pharmaceutical and biotech partners to advance drug development programs, focusing on therapeutic antibodies and small molecule drugs. Salipro Biotech operates in the biopharmaceutical market, serving clients in both industry and academia. The business model revolves around partnerships and internal pipelines, generating revenue through collaborative drug development and licensing agreements. Established in 2016 at Karolinska Institutet, Salipro Biotech has since enabled researchers worldwide to work with challenging drug targets.
Keywords: membrane proteins, drug discovery, therapeutic antibodies, small molecules, nanoparticles, biopharmaceutical, stabilization technology, biotech partnerships, Karolinska Institutet, lipid-containing nanoparticles.